Health AI Central
Peer-Reviewed Publication
Neurooncol Adv2026;8(1):vdag236.January 1, 2026Journal Article

Artificial intelligence-enabled early intracranial volumetric response predicts systemic progression-free survival in the phase III CROWN study.

Shao-Lun Lu1,2, Yu-Cheng Chang3, Chih-Hung Liang3, Po-Lin Chiang3, Kevin Maresca4, Erqi Pollom5, Keith Wilner6, Jen-Tang Lu3, Francesca Toffalorio7, Giuseppe Giaccone8, Chong Duan4
1Department of Radiation Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
2Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
3Vysioneer Inc., Cambridge, Massachusetts, USA.
4Pfizer, Cambridge, Massachusetts, USA.
5Department of Radiation Oncology, Stanford University, Palo Alto, California, USA.
6Pfizer, San Diego, California, USA.
7Pfizer, Milan, Italy.
8Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Manual endpoint assessment is labor-intensive and variable. This study evaluated artificial intelligence (AI)-powered intracranial response assessment and explored imaging prognostic factors in the phase III CROWN trial of advanced treatment-naive anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). METHODS: CROWN randomized patients to lorlatinib or crizotini…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.